Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BRII-179 + elebsiran + pegylated interferon alfa
- Development stage
- Unknown
- Lead developer
- Brii Biosciences
- Modality
- Small Molecules, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular, Subcutaneous
01
Overview
This drug is a **combination therapy** consisting of: - **BRII-179**: a recombinant protein-based therapeutic vaccine targeting hepatitis B virus (HBV), expressing the Pre-S1, Pre-S2, and S HBV surface antigens to induce broad B-cell and T-cell immunity in patients[1]. - **Elebsiran**: a small interfering RNA (siRNA, formerly BRII-835 or VIR-2218) designed to silence HBV gene expression, thereby reducing viral antigens and replication[1]. - **Pegylated interferon alfa (Pegasys, peginterferon alfa-2a)**: an immunotherapy that boosts the innate antiviral immune response via the type I interferon pathway (notably JAK/STAT), used in chronic hepatitis treatments[2][4]. This combination is in clinical development as a **curative functional therapy for chronic hepatitis B infection**, aiming to enhance HBsAg (hepatitis B surface antigen) loss and seroclearance, especially in patients primed with BRII-179[1][3][5][7]. BRII-179 may help select or prime patients for improved immune response to subsequent elebsiran + pegylated interferon therapy[1][3][5]. Developer: Brii Biosciences[1][3][5][7].
- Other names
- pegylated interferon alfapeginterferon alfa-2a
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on BRII-179 + elebsiran + pegylated interferon alfa.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BRII-179 + elebsiran + pegylated interferon alfa.